Pheochromocytoma and paraganglioma (PPGL) require prompt consideration and efficient
diagnosis and treatment to minimize associated morbidity and mortality. Once considered …

Background The lack of an accurate blood biomarker in neuroendocrine tumor (NET)
disease has hindered management. The advance of genomic medicine and the …

Over the past 5 years, a number of notable research advances have been made in the field
of neuroendocrine cancer, specifically with regard to neuroendocrine cancer of the …

Neuroendocrine neoplasms (NENs) are derived from neuroendocrine cell system and can
have benign or malignant characteristics. They are rare tumors, but have been increasing in …

Continuous progress in the diagnostics and treatment of neuroendocrine neoplasms
(NENs), the emerging results of new clinical trials, and the new guidelines issued by medical …

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) arise from neuroendocrine
cells found throughout the gastrointestinal tract and islet cells of the pancreas. The incidence …

Neuroendocrine neoplasms (NENs) are a heterogeneous group of diseases that are
characterized by different behavior and clinical manifestations. The diagnosis and …

Neuroendocrine tumors are a heterogeneous group of neoplasms originating from the
diffuse endocrine system. Depending on primary location and hormonal status, they range in …

Purpose There are few effective biomarkers for neuroendocrine tumors. Precision oncology
strategies have provided liquid biopsies for real-time and tailored decision-making. This has …

Lutetium 177 (177Lu) DOTA-0-Tyr3-Octreotate (DOTATATE) peptide receptor radionuclide
therapy (PRRT) is an effective treatment for advanced gastroenteropancreatic …